The microbial analysis found that participants with schizophrenia had lower microbial richness and diversity than controls, along with marked separation in beta-diversity. The authors used an exploratory random forest model to rank taxa that contributed most strongly to discrimination between the groups. Pseudocitrobacter, Hafnia-Obesumbacterium and Escherichia-Shigella were the leading features in that analysis. The result identifies organisms associated with group membership in this dataset; it does not validate them as diagnostic biomarkers or establish their biological role in schizophrenia.

Several taxa differed in relative abundance between the two groups. Escherichia-Shigella was significantly enriched in the schizophrenia group, with a median relative abundance of 2.377% in group S compared with 0.119% in group H; the false-discovery-rate-adjusted q value was 0.00031 and Cliff’s delta was 0.646. In the opposite direction, Faecalibacterium had a median relative abundance of 2.630% in the patient group and 7.275% in the control group. Agathobacter was also more abundant in controls, with medians of 0.903% in patients and 2.874% in healthy controls. These measurements describe differences in the sampled fecal communities and do not show that the bacteria caused psychiatric symptoms or that they can identify an individual patient reliably.

Untargeted metabolomics also revealed differences between patients and controls, predominantly involving metabolites and pathways associated with amino acid and lipid metabolism. In combination with the microbial findings, the chemical profile was consistent with distinct microbiota–metabolite features in the schizophrenia group. The supplied study abstract does not identify which organisms produced or modified the measured metabolites, nor does it establish the order of events linking schizophrenia, medication, microbial changes and metabolic changes. The two sets of measurements therefore show parallel differences in biological features, rather than a proven causal pathway.

The study’s main constraints are its small sample size, cross-sectional design and antipsychotic exposure. Because the work was cross-sectional, it cannot determine whether the observed microbial and metabolomic differences preceded schizophrenia, developed alongside it or were partly related to treatment. The authors state that medication-related effects could not be separated from disease-specific effects, so the findings should be treated as exploratory observations. They call for confirmation in larger longitudinal cohorts and independent validation datasets. Until such evidence is available, the results indicate that gut microbial composition and untargeted metabolomic profiles differ between this group of patients with schizophrenia and healthy controls, without proving causality, establishing a clinical test or showing that the findings generalize to all people with schizophrenia.

Subject of Research: Gut microbiota and untargeted metabolomic differences in schizophrenia

Article Title: Altered gut microbiota and untargeted metabolomic features in patients with schizophrenia: a case–control study

Article References: Mi, Y., Sun, P., Hao, Q., Yang, Y., Dong, C., Kong, C., Li, L., Zhao, C., & Yin, H. (2026). Altered gut microbiota and untargeted metabolomic features in patients with schizophrenia: a case–control study. Frontiers in Psychiatry, 17, Article 1981601. https://doi.org/10.3389/fpsyt.2026.1981601

Image Credits: AI Generated

DOI: 10.3389/fpsyt.2026.1981601

Keywords: schizophrenia, gut microbiota, untargeted metabolomics, 16S rRNA sequencing, case–control study, amino acid metabolism, lipid metabolism, Escherichia-Shigella, Faecalibacterium, microbiota–metabolite associations, Altered, microbiota

The researchers used five-week-old male C57BL/6J mice, which were acclimatized for one week and then assigned by computer-generated randomization, with body-weight stratification, to four groups of eight. One group received a normal diet, while the other three received a high-fat diet. After 10 weeks on the diets, one high-fat-diet group received saline by gavage, another received the anti-obesity drug orlistat, and the third received raw camel milk at 10 millilitres per kilogram of body weight daily for seven weeks.

The camel milk was collected during mid-lactation in Inner Mongolia, kept frozen at minus 80 degrees Celsius, thawed before administration and delivered without pasteurization. Investigators conducting biochemical assays, sequencing-library preparation and bioinformatics analyses were blinded to group assignment. Compared with untreated high-fat-diet mice, those receiving camel milk weighed significantly less at weeks 13 through 16 and had lighter inguinal and epididymal white adipose tissue.

Their adipocytes also occupied less area on haematoxylin and eosin-stained sections, a histological measure of reduced cellular enlargement. Serum triglycerides and low-density lipoprotein cholesterol fell, while high-density lipoprotein cholesterol rose. Food intake was lower in the camel-milk group during weeks 14 and 15, a finding that may partly account for the weight difference and is one of the study’s central limitations.

Because researchers did not include an isocaloric pair-fed control, they could not separate effects of reduced food consumption from effects potentially attributable to specific components of camel milk. The metabolic effects were not uniform. Camel milk significantly reduced serum alanine aminotransferase and attenuated the lipid droplets seen in liver sections, both consistent with less hepatic steatosis, but its reduction in liver weight was not statistically significant.

Fasting blood glucose, fasting insulin and the homeostasis model assessment of insulin resistance did not differ significantly among the four groups. In the oral glucose tolerance test, camel-milk-treated mice showed an improved glucose-response profile, although the clearest statistical glucose reduction was reported for orlistat. Insulin sensitivity improved significantly with orlistat, whereas the improvement in the camel-milk group was not significant.

Random blood glucose was also lower with orlistat but not significantly lower with camel milk. The result therefore appears to involve improved glucose tolerance alongside improved adiposity and blood lipids, rather than a demonstrated correction of every measure of metabolic dysfunction. Sequencing of bacterial 16S rRNA genes from colonic contents showed that the high-fat diet separated the microbiome from the normal-diet group and that camel milk shifted it only partly back.

Principal coordinate analysis placed the camel-milk group between the normal-control and high-fat-diet clusters, with the dominant separation along the first axis accounting for 68.43% of the variation. At the phylum level, camel milk increased Bacteroidota and reduced Pseudomonadota and Deferribacterota relative abundance compared with the untreated high-fat-diet group. It also suppressed Mucispirillum, Escherichia-Shigella and Faecalitalea, partially restored Bacteroides and increased Parabacteroides.

The unclassified Eubacterium coprostanoligenes group became particularly abundant after treatment. These are compositional findings: they show that taxa changed alongside improved metabolic phenotypes, but they do not demonstrate that any organism caused the improvements. Targeted measurements in colonic contents found that the high-fat diet lowered concentrations of several short-chain fatty acids, including acetic, butyric and propionic acids.

Camel milk raised all eight measured compounds relative to the untreated high-fat-diet group, with acetic and propionic acid returning to levels comparable to those of normal-diet controls. The restoration of these bacterial metabolites is consistent with a mechanism involving the gut-liver axis, through which intestinal organisms and their products could influence liver metabolism. Nevertheless, the short-chain-fatty-acid analysis used only three biological replicates per group, and the researchers emphasized the potential variability of these measurements.

The study also did not identify which dietary substrates or microbial pathways produced the changes, so the milk cannot yet be classified as a prebiotic on the basis of these data alone. Untargeted liver metabolomics revealed a broad but incomplete remodeling of hepatic chemistry. The camel-milk samples clustered between normal controls and high-fat-diet animals in principal component analysis.

In positive-ion mode, researchers identified 443 differential metabolites between normal controls and untreated high-fat-diet mice, compared with 170 between camel-milk and untreated mice; the corresponding negative-ion counts were 244 and 158. Camel milk reversed the high-fat-diet-associated elevations of sphingosine and the sphingomyelin SM(d18:0/16:1(9Z)). Enrichment analysis implicated lipid and sphingolipid signaling, arachidonic acid metabolism, amino-acid pathways, glutathione metabolism, oxidative stress and inflammatory signaling.

These findings identify differential metabolites and enriched metabolic pathways, but the metabolomic analysis alone cannot establish which biochemical reactions caused the metabolic phenotypes or demonstrate changes in metabolic flux. RNA sequencing likewise showed partial correction at the transcriptional level. Compared with untreated high-fat-diet mice, camel-milk-treated livers had 613 differentially expressed genes, including 181 upregulated and 432 downregulated genes; 271 of these genes had also differed between normal controls and high-fat-diet animals.

Changes involved arachidonic acid metabolism, fatty-acid elongation, unsaturated-fatty-acid biosynthesis, glycerolipid metabolism and bile secretion. Among the changes were lower expression of several Cyp4a genes, multiple Acot genes and the glycerolipid genes Aldh3a2, Mgll and Mogat1. The bile-transport gene Abcg5 was upregulated, whereas several other bile-related transcripts changed in the opposite direction.

These findings indicate transcriptional reprogramming, not demonstrated changes in enzyme activity, metabolic flux, bile secretion or reverse cholesterol transport. The researchers did not directly measure 20-hydroxyeicosatetraenoic acid, the relevant output of Cyp4a enzymes, and did not validate the selected transcripts at the protein level. Spearman correlations connected several microbial taxa with metabolic and molecular measurements.

The unclassified Eubacterium coprostanoligenes group was negatively associated with epididymal fat weight at r = −0.846, inguinal fat weight at r = −0.818, triglycerides at r = −0.673 and the oral-glucose-test area under the curve at r = −0.580. Faecalitalea showed opposite associations with some fat and lipid measures. The Eubacterium group was positively associated with metabolites linked to glutathione, amino-acid and carbohydrate metabolism and negatively associated with sphingolipids and unsaturated fatty acids, while Escherichia-Shigella displayed largely opposing patterns.

It also correlated with lipid-metabolism genes, including Cyp2c70, several Cyp4a and Acot genes, Aldh3a2 and Ugt1a7c. Such cross-omics associations strengthened the proposed link between the altered microbiome and hepatic lipid regulation, but they remain correlational and cannot establish direction of effect or mediation. Several further boundaries constrain interpretation.

The experiment included only male mice, so sex-specific responses remain unknown. It lacked a comparison with conventional bovine or goat milk and therefore cannot show that the effects were unique to camel milk. Raw milk was used to preserve potentially heat-sensitive constituents such as lactoferrin, lysozyme, immunoglobulins and insulin-like proteins, but trace microbial products or enzymes could also have contributed.

The multi-omics components used different sample sizes, including three replicates for short-chain fatty acids and transcriptomics, and the study tested whole milk rather than isolated molecules. The defensible conclusion is that camel milk produced measurable metabolic and molecular changes in this mouse model, with a possible role for microbial and short-chain-fatty-acid changes in liver lipid remodeling. Fecal microbiota transfer, microbial depletion, pair-feeding, other-milk controls and eventual human studies would be needed to determine whether camel milk itself has a reproducible, causal and clinically useful effect.

Subject of Research: Camel milk effects on gut microbiota and hepatic lipid metabolism in high-fat-diet-fed mice

Article Title: Camel milk is associated with ameliorated high-fat diet-induced obesity and metabolic disorders via modulation of gut microbiota and remodeling of hepatic lipid metabolism: a multi-omics analysis

Article References: Yang, B., Wang, J., Pan, W., Liang, H., & Zhao, H. (2026). Camel milk is associated with ameliorated high-fat diet-induced obesity and metabolic disorders via modulation of gut microbiota and remodeling of hepatic lipid metabolism: a multi-omics analysis. Frontiers in Nutrition, 13, Article 1913436. https://doi.org/10.3389/fnut.2026.1913436

Image Credits: AI Generated

DOI: 10.3389/fnut.2026.1913436

Keywords: camel milk, gut microbiome, gut-liver axis, diet-induced obesity, short-chain fatty acids, hepatic steatosis, lipid metabolism, multi-omics, metabolic disorders, mouse model, Camel, milk

The investigators focused on modification of RNF14 at cysteine 407. Adenoviral transduction was used to introduce either wild-type or palmitoylation-deficient RNF14 constructs, allowing the researchers to test the functional importance of this site. The study reports that palmitoylation stabilized RNF14 and supported the protein’s role in lipid metabolism and tumor growth.

Silencing ZDHHC9 disrupted RNF14 palmitoylation, impaired lipid metabolism and strongly suppressed tumor progression in the tested models. Together, these observations support a causal regulatory relationship between the modification, RNF14 stability and the measured growth-related phenotypes within the experimental system. Protein-interaction and modification assays identified ZDHHC9, a zinc finger DHHC-type palmitoyltransferase, as the enzyme that catalyzed RNF14 palmitoylation.

The study then traced increased ZDHHC9 expression to GCN5-mediated acetylation of YY1. According to the results, acetylation of YY1 activated ZDHHC9 expression, forming a four-part regulatory axis: GCN5 acetylates YY1, activated YY1 raises ZDHHC9 expression, ZDHHC9 promotes RNF14 palmitoylation at cysteine 407, and stabilized RNF14 supports lipid metabolic reprogramming and colorectal cancer progression. Researchers used western blotting to assess protein expression, immunoprecipitation to examine protein–protein interactions and immunofluorescence to visualize relevant cellular features.

Post-translational modifications were also analyzed. RNF14 palmitoylation levels were measured using an acyl resin-assisted capture assay, and cell viability was examined with a Cell Counting Kit-8 assay. These complementary approaches were used to connect the molecular modification with changes in RNF14 stability, lipid metabolism, cell viability and tumor behavior.

The authors characterized the findings as evidence for a palmitoylation-dependent mechanism regulating lipid metabolism in colorectal cancer and proposed the GCN5–YY1–ZDHHC9–RNF14 axis as a potential therapeutic target. That proposal remains preclinical. The supplied study evidence does not include a human clinical trial, patient outcomes, treatment safety data or evidence that inhibiting any component of the pathway would benefit people with colorectal cancer.

The article was published in Cellular and Molecular Life Sciences on 22 October 2026 as an open-access, peer-reviewed article shared ahead of the final version of record, with further edits still possible.

Subject of Research: Preclinical analysis of a GCN5–YY1–ZDHHC9–RNF14 pathway regulating lipid metabolism and tumor growth in colorectal cancer models.

Article Title: GCN5-mediated acetylation of YY1 enhances ZDHHC9-dependent palmitoylation of RNF14 and promotes colorectal cancer progression

Article References: Li, B.-F., Li, G.-Q., Lv, F.-Y., Li, Q.-H., & Lv, L. (2026). GCN5-mediated acetylation of YY1 enhances ZDHHC9-dependent palmitoylation of RNF14 and promotes colorectal cancer progression. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06493-7

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06493-7

Keywords: colorectal cancer, RNF14 palmitoylation, GCN5, YY1 acetylation, ZDHHC9, lipid metabolism, cancer cell lines, mouse xenografts, GCN5-mediated, acetylation, enhances, ZDHHC9-dependent

The review reports that HCC cells commonly increase lipid uptake, de novo lipogenesis, or the synthesis of fatty acids within the cell, and fatty acid oxidation, which breaks fatty acids down to generate energy. These changes provide both fuel and molecular building blocks for proliferation. Lipids also act as signalling molecules and structural components of cell membranes, allowing metabolic alterations to influence membrane composition, epigenetic regulation, oxidative stress and other processes associated with invasion and metastasis. The article notes that most patients are diagnosed when the disease is already advanced and that lipid metabolism may help determine response to treatment.

Specific transport proteins and biosynthetic enzymes offer several possible points of intervention. CD36, a membrane protein involved in fatty acid uptake, can activate Src/PI3K/Akt/mTOR signalling and has been linked to growth and metastasis. It may also preferentially promote uptake of monounsaturated fatty acids. Fatty acid-binding protein 5, or FABP5, can activate HIF-1, increase the expression of lipid-storage genes and suppress fatty acid oxidation; experimental inhibition of FABP5 has made tumour cells more susceptible to ferroptosis. On the synthesis side, the review highlights acetyl-CoA carboxylase, ATP citrate lyase, fatty acid synthase and stearoyl-CoA desaturase 1. High expression of lipogenesis-associated genes has been associated with poorer survival in HCC, while increased stearoyl-CoA desaturase 1 activity can raise the ratio of monounsaturated to saturated fatty acids and enhance invasive behaviour.

Reprogramming of cholesterol and phospholipid metabolism adds another layer to the disease. Stearoyl-CoA desaturase 1 inhibition and ATP citrate lyase inhibition have produced antitumour effects in experimental systems, with ATP citrate lyase inhibition also linked to stronger antitumour immunity and improved lenvatinib efficacy. Accumulation of phosphatidylcholine, palmitic acid and cholesterol may alter membrane properties, endoplasmic-reticulum stress and oxidative balance. It can also promote lipid modification of proteins through palmitoylation, a process influenced by ZDHHC-family proteins. Cholesteryl ester synthesis is regulated in part by sterol regulatory element-binding protein 2 and the enzyme sterol acyltransferase 1, which converts free cholesterol into cholesteryl esters for storage in lipid droplets. Inhibiting sterol regulatory element-binding protein 2 has reduced cholesteryl ester synthesis and worked synergistically with sorafenib in preclinical models, although the review notes a paradox: blocking cholesteryl ester synthesis may also increase arachidonic acid metabolism and thereby favour tumour development in some settings.

Lipophagy, the turnover of lipids stored in droplets, presents a further metabolic control point. The review describes evidence that PPARα-associated lipophagy can support advanced HCC, whereas inhibiting the process has promoted chemoresistance through lipid-droplet accumulation. Under conditions of glutamine deprivation, lipophagy can also preserve redox homeostasis. These apparently opposing effects illustrate why a single metabolic intervention may not produce a uniform effect across the heterogeneous lipid landscape of HCC. They also show why inhibiting one enzyme or transport mechanism can have different consequences in tumour cells, stromal cells and immune cells.

Beyond tumour cells, lipid changes can suppress or redirect immune activity, creating a microenvironment that helps the cancer evade immune control. Excess fatty acid uptake by CD36 has been associated with CD8-positive T-cell exhaustion and, in experimental settings, ferroptosis. Fatty acid oxidation supports CD8-positive T-cell function, but excessive oxidation can impair it. Regulatory T cells can be recruited through the CCL20/CCR6 axis, and CD36 inhibition has shown synergy with anti-PD-1 treatment in models. In natural killer and NKT cells, long-chain acylcarnitine accumulation can restrain NKT-cell proliferation, while cholesteryl ester accumulation can promote lipid peroxidation and impair NKT-cell function. The review also reports that elevated serum cholesteryl ester enhanced natural killer-cell activity in mice, underscoring the difficulty of predicting the immune consequences of altering systemic or local lipid levels.

Myeloid cells and cancer-associated fibroblasts also undergo lipid-dependent changes. Lipid accumulation can shift tumour-associated macrophages from a more inflammatory M1 state toward an M2 state. Oxidized low-density lipoprotein and cholesteryl esters can support TREM2-positive macrophages that promote invasion and CD8-positive T-cell dysfunction, while FABP5 can drive M2 polarization through PPARγ. Although M2 macrophages rely on fatty acid oxidation and can express PD-L1, inhibiting that oxidation has shifted macrophages toward a more antitumour phenotype in experimental work. Pro-tumour cancer-associated fibroblasts can increase fatty acid synthase, acetyl-CoA carboxylase and stearoyl-CoA desaturase 1 and release lipids that support tumour growth. CD36-positive fibroblasts expressing macrophage inhibitory factor can suppress T-cell immunity, and CAF-derived extracellular vesicles have been linked to proliferation, metastasis, drug tolerance and resistance to ferroptosis. These findings identify stromal metabolism as an active component of HCC rather than a passive surrounding structure.

Several lipid-directed interventions have entered clinical testing, although the evidence remains preliminary. PLT012, an anti-CD36 antibody, is described as being in a phase I trial and has received US Food and Drug Administration Fast Track designation. Another CD36-targeting candidate, VT1021, is also being tested, with the review reporting a disease control rate of 42.9% in a clinical trial. Preclinical findings have also examined FASN inhibition, which can increase MHC class I expression and potentially improve the activity of immune checkpoint inhibitors. Orlistat has sensitized sorafenib-resistant HCC models, while inhibition of stearoyl-CoA desaturase 1 has worked synergistically with tyrosine kinase inhibitors. Statins, which inhibit cholesterol synthesis, have shown promise in laboratory combination strategies, including resensitization of tumour cells to sorafenib, and nanoparticle delivery may improve the efficacy of metabolic interventions. Results with statins in patients have been mixed, however, with early studies suggesting a survival benefit but later trials producing less consistent evidence.

The review’s central conclusion is that lipid metabolism is both a source of metabolic support for HCC and a mechanism connecting tumour cells with immune and stromal cells. Agents that suppress cholesteryl ester synthesis or inhibit lipid-biosynthetic enzymes have shown synergy with established anticancer drugs in preclinical systems, but translation into routine care remains limited. Direct manipulation of metabolic pathways can trigger compensatory mechanisms and may damage the metabolic integrity of beneficial immune cells. Clinical studies are constrained by small samples, heterogeneous patient populations, uncertainty about effective intratumour exposure and the broad effects of drugs such as statins. The authors therefore call for larger trials, more precise selection of patients whose tumours have identifiable lipid alterations and more rigorous study designs. Preclinical promise is substantial, but the review concludes that metabolism-targeted therapy is not yet an established clinical approach for most people with HCC.

Subject of Research: Lipid metabolism reprogramming and therapeutic strategies in hepatocellular carcinoma

Article Title: Advances in lipid metabolism reprogramming in hepatocellular carcinoma

Article References: Advances in lipid metabolism reprogramming in hepatocellular carcinoma. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: hepatocellular carcinoma, lipid metabolism, tumour microenvironment, immune evasion, lipophagy, CD36, fatty acid oxidation, lipogenesis, cancer-associated fibroblasts, metabolic therapy, Advances, lipid

The results identify associations rather than establish that metabolism directly causes T-cell exclusion, and the authors emphasize that the spatial analysis included only 12 patients, with particularly few usable immune-cell regions in the low-infiltration group. Previous work in this series of patients had linked denser pretreatment infiltration of CD8-positive T cells to a complete pathological response after neoadjuvant chemoradiotherapy. In the new analysis, four of six tumors with the highest CD8 scores showed a complete response, whereas none of the six with the lowest scores did.

That association prompted the team to search for cancer-cell-intrinsic and immune-cell features that differed between inflamed and excluded regions. Using the GeoMx Digital Spatial Profiler, the researchers profiled the whole transcriptome in treatment-naive, stage II or III esophageal or gastroesophageal-junction adenocarcinomas. A pathologist selected regions of interest, after which cancer cells identified by cytokeratin staining and immune cells identified by CD45 staining were analyzed separately.

After quality control, 34 cancer-cell segments and 22 immune-cell segments remained for further study, drawn from 41 regions across the 12 selected tumors. The selected patients represented the extremes of CD8 infiltration: the final set had a median of 20.6 CD8-positive cells per square millimeter in the low group and 224.2 per square millimeter in the high group. Cancer-cell profiles separated mainly according to the tumor’s CD8-infiltration status.

Regions from the same patient generally clustered together, suggesting that patient-specific programs were important, although one tumor contained both CD8-low and CD8-high transcriptional regions. These cancer cells expressed higher levels of APOA1 and APOA4, lipid transporters associated with cholesterol handling; PPARGC1A, which regulates mitochondrial biogenesis and oxidative metabolism; and OXCT1, a mitochondrial enzyme involved in ketone-body metabolism. Such metabolic differences were more prominent than differences in canonical oncogenic pathways.

Pathway analysis reinforced the metabolic pattern. Of 400 differentially expressed pathways, lipid-related programs—including high-density lipoprotein and chylomicron remodeling, lipoprotein remodeling and ketone metabolism—were elevated in cancer cells from CD8-low tumors. In contrast, CD8-high regions showed stronger antigen-presentation, interferon-alpha signaling, interleukin-7 signaling and Fas-mediated immune-apoptosis pathways.

The low-infiltration cancer cells also displayed several immune-suppressive features: reduced expression of antigen-presentation components in half of the affected patients, increased checkpoint-related transcripts, and higher expression of the tryptophan-depleting enzyme IDO1. At the same time, they expressed cancer-testis antigens that can elicit T-cell responses, underscoring the possibility that tumor cells may suppress presentation of antigens capable of attracting an immune response. The immune-cell compartments pointed in a similar direction, although the evidence was less balanced.

Only four CD45-positive segments from three CD8-low tumors passed quality control, compared with 18 segments from five CD8-high tumors, because immune-cell-depleted regions often yielded too few CD45-positive cells. In the available low-infiltration material, APOA1, APOA4, LGALS2, MMP1 and INHBA were enriched; these genes are associated with lipid metabolism or suppressive myeloid-cell populations. Single-sample pathway analysis also identified steroid-hormone metabolism, amino-acid and peptide transport, ubiquinol biosynthesis and the PGC-1alpha program in the low-infiltration immune compartments.

PGC-1alpha is a central regulator of mitochondrial biogenesis, making its enrichment compatible with a population of myeloid cells that depends more on oxidative phosphorylation than glycolysis. The researchers then tested whether the association appeared in a larger, independent dataset. They analyzed bulk messenger-RNA profiles from 65 treatment-naive, chromosomally unstable esophageal adenocarcinomas in The Cancer Genome Atlas and divided patients by the median cytotoxic T-lymphocyte signature.

Tumors in the lower half ranked highly for mitochondrial translation, respiratory electron transport, the tricarboxylic acid cycle and oxidative phosphorylation. Single-sample analysis also associated cholesterol metabolism with greater macrophage infiltration and ketone-body metabolism with lower CD8-positive T-cell infiltration. These results support a broad association between mitochondrial metabolic programs and lymphocyte-poor tumors, but the retrospective bulk data cannot show that the pathways caused the difference in immune composition.

Fresh tissue provided a functional test of the transcriptomic observations. Using SCENITH, a flow-cytometry assay that estimates dependence on glycolysis or mitochondrial oxidative phosphorylation from changes in protein synthesis, the team profiled five resected tumors, including esophageal, gastroesophageal-junction and gastric adenocarcinomas. Three specimens were dominated by macrophages and classified as T-cell-low, whereas two lymphocyte-rich tumors included a microsatellite-instable cancer used as a positive control.

Macrophage-like cells from the T-cell-low cancers showed greater mitochondrial dependence, while those from lymphocyte-rich tumors were more glycolysis-dominant. Because the five specimens differed in anatomical origin, prior treatment and immune composition, the experiment supports the proposed metabolic association but does not isolate tumor biology from specimen-level differences. Separate co-culture experiments offered a possible mechanism.

Cancer cell lines with greater oxidative-phosphorylation reliance tended to produce a lower ratio of the macrophage marker CD80 to the alternative-activation marker CD163 than lines relying more on glycolysis, suggesting a shift toward a less inflammatory macrophage phenotype. The result varied among monocyte donors, and the most glycolytic line did not increase the CD80-to-CD163 ratio, indicating that cytokines, direct cell contact and other factors also shape macrophage state. The experiment therefore supports an association between tumor-cell metabolism and macrophage polarization rather than proving that OXPHOS alone causes suppression.

The authors noted that lipid-rich environments can favor mitochondrial respiration in regulatory and myeloid cells, while providing less favorable metabolic conditions for antitumor T cells. Together, the findings nominate lipid metabolism and mitochondrial respiration as possible contributors to the T-cell-excluded state in esophageal adenocarcinoma, while also highlighting reduced antigen presentation as a complementary mechanism. They provide a rationale for testing metabolic interventions alongside immune activation, but they do not demonstrate that such treatment will improve outcomes in patients.

The study was limited by its small selected cohort, unequal immune-segment numbers, retrospective validation dataset and heterogeneous ex vivo samples. The authors have initiated a clinical trial using metformin as a metabolic modulator to test more directly whether changing metabolism can modify the antitumor immune response. Until controlled clinical results are available, the central conclusion is that oxygen-consuming, lipid-linked metabolic states mark esophageal adenocarcinomas that exclude CD8-positive T cells and may help explain resistance to existing immune-directed therapy.

Subject of Research: Spatial analysis of metabolic programs associated with T-cell exclusion in esophageal adenocarcinoma

Article Title: Spatial transcriptomic sequencing identifies lipid metabolism and mitochondrial respiration as central features of T cell excluded esophageal adenocarcinomas

Article References: Sanders, J., Hahn, N., Bos, E. N., van Schie, D. M., Nijman, I. J., van Grieken, N. C. T., van der Peet, D. L., van Laarhoven, H. W. M., Grootjans, J., Bijlsma, M. F., Van den Bossche, J., de Gruijl, T. D., & Derks, S. (2026). Spatial transcriptomic sequencing identifies lipid metabolism and mitochondrial respiration as central features of T cell excluded esophageal adenocarcinomas. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03635-3

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03635-3

Keywords: esophageal adenocarcinoma, spatial transcriptomics, T-cell exclusion, lipid metabolism, mitochondrial respiration, oxidative phosphorylation, tumor microenvironment, macrophages, antigen presentation, immune suppression, Spatial, transcriptomic

Tianxiang 1 pigeons displayed several features consistent with more developed intestinal function. In the reported histological measurements, they had significantly greater villus height, a higher villus-height-to-crypt-depth ratio and greater goblet-cell density than Mimas pigeons, while their intestinal walls were thinner. These structural measures can indicate differences in absorptive and immune characteristics, but the researchers did not directly test digestive performance. The study therefore supports the conclusion that the strain possesses intestinal features associated with improved development and immune function, rather than demonstrating a measured clinical or production benefit.

The microbial communities also differed markedly, particularly in the ileum. Functional enrichment associated Tianxiang 1 microbiota mainly with intestinal growth and immune regulation. By contrast, the microbial functions linked to Mimas pigeons were dominated by carbohydrate metabolism and lipid biosynthesis. Two genera, Turicibacter and Lactobacillus, occurred in the candidate association pattern characteristic of Tianxiang 1 pigeons and were associated with intestinal morphological measurements. These findings connect the strain’s gut biology with its histological profile, although the analysis cannot determine whether particular organisms caused the tissue differences or whether the host environment shaped the microbes.

Breast-muscle analyses pointed to a contrasting pattern in Mimas pigeons. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses showed significant enrichment of lipid-metabolism-related pathways in their breast muscle. Acinetobacter and Pseudomonas were positively associated with the expression of KIF2C, BIRC5, PRC1 and RACGAP1, and negatively associated with glycolytic intermediates. Because the study was exploratory, these relationships should not be interpreted as proof that either bacterial genus drives changes in muscle metabolism, fat deposition or meat quality. They are candidate gut-muscle links derived from statistical associations across biological layers.

Taken together, the results suggest that the two strains may differ through coordinated relationships between gut condition, microbial function and muscle metabolism. Tianxiang 1 pigeons combined intestinal features associated with growth and immunity with a microbiota linked to those traits. Mimas pigeons showed an alternative pattern in which lipid-related muscle pathways and selected gut bacteria were associated with changes in gene expression and glycolytic metabolism, a pathway relevant to intramuscular fat deposition. The work offers a multi-omics framework for investigating the biological basis of meat-quality differences, but the limited population, breed-level scope and observational design prevent firm generalization. Establishing causality would require controlled interventions, direct functional measurements and validation in larger, independent samples of pigeons.

Subject of Research: Associations among pigeon gut microbiota, intestinal morphology, breast-muscle gene expression and meat-quality differences between two strains.

Article Title: Gut microbiota and multi-omics analysis identify candidate gut-muscle associations underlying breast muscle quality differences between Mimas pigeon and pigeon Tianxiang 1 strain

Article References: Li, W., Zhang, L., Cen, X., Wang, X., Liao, Z., Wu, Y., Ma, Z., Guo, J., Song, J., Lu, L., & Lin, S. (2026). Gut microbiota and multi-omics analysis identify candidate gut-muscle associations underlying breast muscle quality differences between Mimas pigeon and pigeon Tianxiang 1 strain. BMC Genomics. https://doi.org/10.1186/s12864-026-13480-6

Image Credits: AI Generated

DOI: 10.1186/s12864-026-13480-6

Keywords: pigeon gut microbiota, breast muscle, meat quality, multi-omics, intestinal morphology, microbiome, transcriptomics, metabolomics, lipid metabolism, microbiota, analysis, identify

The study was designed retrospectively and cross-sectionally at a single Grade III Class A traditional Chinese medicine hospital in China. Between October and December 2025, investigators enrolled adults who completed colonoscopy and had compatible clinical records, blood-test results and colonoscopy findings. Patients were excluded if they had conditions that could substantially distort inflammatory or physiological measurements, including severe organ dysfunction, recent active infection, chronic inflammatory or autoimmune disease, recent major trauma or surgery, pregnancy or lactation, and current or previous malignancy. The final sample included 289 people with colorectal polyps and 163 without them, giving a polyp prevalence of 63.27 percent. Because the design was cross-sectional and confined to one hospital, the findings describe associations in this cohort rather than causes or prospective prediction.

Colorectal polyps were classified from colonoscopy findings and subsequent histopathology, with inflammatory polyps, colonic adenomas and other benign epithelial polyps counted as outcomes. CALLY was calculated from three fasting blood measurements: albumin in grams per liter multiplied by the absolute lymphocyte count in units of 10 to the ninth per liter, then divided by C-reactive protein in milligrams per liter. The index was considered both continuously and in four equal groups, from the lowest quartile, Q1, to the highest, Q4. Researchers constructed three logistic regression models: an unadjusted model, a model adjusting for gender, age, body mass index, diabetes, Traditional Chinese Medicine constitution, tongue color, tongue morphology and gastric polyps, and a further model that also included triglycerides and high-density lipoprotein cholesterol.

No statistically significant association between CALLY and polyps appeared in the progressively adjusted models. In the fully adjusted model, the odds ratios for colorectal polyps in Q2, Q3 and Q4, compared with Q1, were 0.81, 1.03 and 0.81, respectively; their 95 percent confidence intervals were 0.39 to 1.67, 0.49 to 2.14 and 0.41 to 1.61, and all corresponding P values exceeded 0.05. Polyp prevalence did not differ significantly across the four CALLY groups, with P equal to 0.76. The model’s area under the receiver operating characteristic curve was 0.85, and Hosmer–Lemeshow tests indicated good calibration, but these measures describe the model as a whole and do not indicate that CALLY contributed independently.

Sensitivity analyses produced the same central result. When CALLY was entered as a continuous variable, backward selection removed it from the final model; its estimated odds ratio was 1.000, with a 95 percent confidence interval of 1.000 to 1.001 and P equal to 0.22, while its addition to explanatory power was negligible. Natural splines with three degrees of freedom provided no evidence of a nonlinear or threshold relationship, with a likelihood ratio P value of 0.881. Results also remained unchanged when tongue signs or gastric polyps were removed from the adjusted model and when observations at the extreme 5th and 95th percentiles of CALLY were excluded. Interaction tests found no evidence that the association varied by gender, age, diabetes status, Traditional Chinese Medicine constitution or gastric polyps.

Several other variables were associated with colorectal polyps in the adjusted analyses. Male gender had an odds ratio of 0.56 in Model 2 and 0.57 in Model 3, indicating lower odds in this cohort rather than greater odds; the authors nevertheless listed sex among the factors consistently associated with risk. Advanced age was associated with higher odds, with an odds ratio of 1.04 per year in both models, meaning a 4 percent increase in odds for each additional year within this dataset. Diabetes was associated with substantially higher odds, with an odds ratio of 3.82 and a 95 percent confidence interval of 1.45 to 10.06 in Model 2, while gastric polyps were associated with an odds ratio of 2.11 and a 95 percent confidence interval of 1.26 to 3.53.

Traditional Chinese Medicine constitution, particularly the phlegm-dampness category, showed a large but statistically imprecise association with polyps. In Model 2, its odds ratio was 14.33, with a very wide 95 percent confidence interval of 3.60 to 57.05; in Model 3, the odds ratio was 15.50, with a confidence interval of 3.82 to 62.98. Only a small number of participants were classified with this constitution, making the estimate unstable. The investigators therefore treated the result as preliminary rather than evidence of a stable risk factor, and they called for independent validation in larger prospective cohorts. The constitution and tongue assessments were performed by trained practitioners who were blinded to laboratory results and colonoscopy findings, with a third senior practitioner resolving disagreements.

The researchers also tested whether triglycerides or high-density lipoprotein cholesterol could explain any relationship between CALLY and polyps through mediation analysis. Neither candidate pathway met the study’s statistical criterion. CALLY was not significantly associated with triglycerides or with high-density lipoprotein cholesterol, and neither lipid measure was significantly associated with polyps in the mediation models. The direct and total effects of CALLY were also non-significant, with all relevant P values above 0.05. Although CALLY correlated with triglycerides at r equal to −0.12 and with high-density lipoprotein cholesterol at r equal to 0.18, those correlations did not translate into detectable mediation in this cohort. The analysis was exploratory, and the sample was too small to exclude small or moderate indirect effects confidently.

The interpretation depends heavily on the population and the study’s statistical limits. A post-hoc calculation assumed an odds ratio of 1.5 for the highest versus lowest CALLY quartile, a two-sided alpha of 0.05, a sample of 452 and polyp prevalence of 63 percent; the resulting power was only 41.6 percent. Thus, the null findings mean that this study did not detect an independent association, not that every possible association has been ruled out. The cohort was clinically enriched: abdominal pain was more common among patients without polyps, at 34.36 percent versus 14.53 percent, and gastric polyps were also strongly associated with colorectal polyps. Differences in baseline risk and comorbidity structure may help explain why this inpatient study reached a different conclusion from an earlier health-screening cohort that associated higher CALLY scores with lower polyp risk, particularly among women.

Other limitations further constrain generalization. CALLY and lipid values were measured only once, leaving the analysis vulnerable to biological variation and measurement error. The retrospective dataset did not include detailed dietary habits, physical activity, family history of colorectal cancer or polyps, or anti-inflammatory medication use, so residual confounding cannot be excluded. Subgroup analyses were limited by small numbers of participants, and the findings cannot establish whether CALLY predicts future incident polyps because exposure and outcome were assessed in a cross-sectional hospital sample. On the evidence presented, routine CALLY testing for colorectal polyp risk had limited clinical utility in hospitalized gastroenterology patients, while larger multicenter prospective studies would be needed to determine whether the index has value in screening populations or underwrites any clinically useful lipid pathway.

Subject of Research: Association of the CALLY index with colorectal polyp risk in hospitalized gastroenterology patients

Article Title: CALLY is not associated with colorectal polyps risk: a systematic evaluation and mechanism exploration controlling for traditional factors and Traditional Chinese Medicine constitution

Article References: Zhang, K., Wu, X., Lin, F., Chen, B., & Han, Y. (2026). CALLY is not associated with colorectal polyps risk: a systematic evaluation and mechanism exploration controlling for traditional factors and Traditional Chinese Medicine constitution. Frontiers in Public Health, 14, Article 1953202. https://doi.org/10.3389/fpubh.2026.1953202

Image Credits: AI Generated

DOI: 10.3389/fpubh.2026.1953202

Keywords: CALLY index, colorectal polyps, inflammation, risk assessment, gastric polyps, diabetes, Traditional Chinese Medicine, lipid metabolism, cross-sectional study, CALLY, associated, colorectal

At the heart of the disease lies a genetic lesion with extraordinary penetrance. Loss or inactivation of the VHL tumour suppressor gene occurs in up to 90 percent of ccRCC cases, and this single event reshapes the entire metabolic landscape of the tumour. Under normal conditions, the VHL protein tags hypoxia-inducible factors, or HIFs, for degradation when oxygen is plentiful. When VHL function is lost, HIF-α accumulates even in well-oxygenated tissue, producing what researchers call a pseudohypoxic state. In this state, the tumour behaves as though it were starved of oxygen, activating a transcriptional programme that supports proliferation, angiogenesis, invasion and metastasis.

This pseudohypoxic switch is far more than a curiosity of gene regulation. HIF-driven transcription reprograms how ccRCC cells acquire and process nutrients, redirecting glucose into glycolysis even when mitochondria could still burn it, promoting the uptake and storage of lipids, and altering how amino acids are scavenged and recycled. The result is a cancer cell that looks and behaves metabolically unlike its healthy neighbours, a difference that decades of cancer metabolism research have suggested should be exploitable with drugs.

The review catalogues the extent of this rewiring across several interconnected pathways. Altered glucose metabolism stands out prominently: ccRCC cells increase glucose uptake through transporters such as GLUT1 and, notably, SGLT2, a transporter better known as a target of diabetes drugs. Glycolytic enzymes including HK2, PFKFB3, PKM2 and PDK1 are upregulated or differentially regulated, reinforcing the Warburg-like preference for fermenting glucose into lactate. Lactate itself, once considered a waste product, is now understood as a signalling molecule and fuel that shapes both tumour behaviour and the surrounding microenvironment, with LDHA and monocarboxylate transporters emerging as points of control.

Lipid metabolism tells an equally striking story. Clear cell tumours are named for their characteristic cytoplasmic droplets of fat and glycogen, and the review describes how extensive lipid accumulation is not merely a by-product but an active adaptation. Enzymes and transporters governing lipid synthesis, uptake and oxidation, including ACLY, ACC, FASN, SCD1, CD36 and CPT1A, are reconfigured to supply membranes, signalling molecules and energy stores. Abnormal amino acid metabolism, particularly involving glutamine, tryptophan and arginine, adds a further layer, supplying nitrogen and carbon for biosynthesis while depleting nutrients that immune cells need to function.

That last point connects metabolism directly to one of the central clinical challenges in kidney cancer. The metabolic activities of tumour cells help construct an immunosuppressive tumour microenvironment. Lactate-rich, nutrient-depleted surroundings can blunt the activity of cytotoxic T cells and favour regulatory immune populations, and altered tryptophan and arginine catabolism is a well-established mechanism of immune suppression. This may help explain why immune checkpoint inhibitors, which have transformed treatment for many cancers, produce durable responses in only a subset of ccRCC patients, and why metabolic interventions could potentially restore sensitivity to immunotherapy.

The therapeutic implications form the core of the review’s argument. Each metabolic node identified as dysregulated represents a potential drug target, and the authors enumerate them systematically: glucose transporters GLUT1 and SGLT2, the glycolytic enzymes HK2, PFKFB3, PKM2 and PDK1, lactate regulators LDHA and the MCT family, lipid pathway proteins ACLY, ACC, FASN, SCD1, CD36 and CPT1A, and enzymes of glutamine, tryptophan and arginine metabolism. Several agents directed at these targets have already entered clinical evaluation, although the review is careful to note that progress varies considerably between targets, and that clinical translation remains uneven across the metabolic landscape.

The complexity of tumour metabolism, however, imposes real constraints on single-target strategies. Cancer cells display remarkable metabolic plasticity: when one pathway is blocked, they can compensate by routing flux through parallel routes, drawing on alternative fuels, or reprogramming upstream regulators. This buffering capacity means that inhibiting a single enzyme, however central it appears in preclinical models, may produce modest or transient clinical effects. The review acknowledges this limitation candidly, positioning metabolism-targeting not as a standalone solution but as one component of a broader therapeutic architecture.

The path forward, the authors argue, will likely depend on combination therapies and multi-target inhibitors designed to close the escape routes that tumours use to bypass metabolic blockade. Improved biomarkers are equally important, since patients/ tumours differ in their metabolic dependencies, and approaches capable of accounting for metabolic heterogeneity within individual tumours will be needed to match the right drug to the right biology. Integrating metabolic interventions with immune checkpoint inhibitors and other established treatments, including the VEGF-targeted therapies already standard in ccRCC, could offer a route toward overcoming resistance and building genuinely personalised treatment strategies.

What makes this synthesis compelling is the convergence of genetics and metabolism in a single disease. Because VHL loss is nearly universal in ccRCC, the pseudohypoxic, lipid-laden, glycolysis-dependent phenotype it produces is a shared vulnerability rather than a rare subtype feature, giving the field an unusually consistent target landscape. If combination regimens can be designed to exploit that consistency while accommodating tumour-to-tumour variability, the metabolic rewiring that has long made clear cell renal cell carcinoma distinctive may finally become the very thing that makes it treatable.

Subject of Research: Metabolic reprogramming and therapeutic targets in clear cell renal cell carcinoma

Article Title: Metabolic vulnerabilities open new therapeutic possibilities in clear cell renal cell carcinoma

Article References: Metabolic vulnerabilities open new therapeutic possibilities in clear cell renal cell carcinoma. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: clear cell renal cell carcinoma, kidney cancer, metabolism, VHL, HIF, glycolysis, lipid metabolism, immunotherapy, drug targets, tumour microenvironment, pseudohypoxia, combination therapy

Chronic kidney disease becomes steadily more common with age, and one of its quiet drivers is the accumulation of senescent cells, particularly in the proximal tubular epithelial cells, or TECs. These cells perform the demanding job of reabsorbing filtered substances and are essential to kidney function. Senescence can initially serve a protective purpose, halting cells that have suffered DNA damage before they turn cancerous. But when senescent cells linger, they secrete inflammatory and profibrotic signaling molecules that injure surrounding tissue, promote scarring and gradually erode organ performance. Understanding what tips a stressed TEC into persistent senescence has therefore become a central question in kidney aging research.

The Amsterdam team focused their attention on lysosomes, the cellular compartments that break down and recycle biological material. Lysosomal function depends on a specialized set of membrane phospholipids, most notably bis(monoacylglycerol)phosphate, or BMP, a lipid that helps organize the internal architecture of the lysosome and supports its digestive activity. Earlier studies had reported that BMP abundance rises during aging and in kidney disease, but the lipid’s exact contribution to senescence remained murky. That gap led the researchers to PLA2G15, a phospholipase enzyme resident in the lysosome that participates in BMP breakdown and broader lipid metabolism.

The first evidence came from a comparison of young and aged mouse kidneys. In older animals, the researchers observed greater accumulation of BMP lipids alongside increased expression of the Pla2g15 gene, together with molecular signatures of cellular senescence. While these observations were associative rather than causal, they established that lysosomal lipid metabolism shifts in parallel with kidney aging, setting the stage for a more direct experimental test of whether the enzyme actually influences the senescence program.

To probe that relationship, the team used CRISPR/Cas9 gene editing to disrupt Pla2g15 in immortalized mouse proximal tubular epithelial cells. Two independently generated knockout lines showed sharply reduced PLA2G15 protein levels and enzyme activity, giving the researchers a clean system in which to examine the consequences of losing the enzyme. Lipidomic profiling of these cells revealed widespread remodeling of phospholipid metabolism. Total BMP abundance rose, as did levels of its precursor, lysophosphatidylglycerol, but the composition of the BMP pool changed in a more telling way: several long-chain unsaturated BMP species were actually reduced. In other words, PLA2G15 does not simply control how much BMP is present; it shapes which specific molecular species of the lipid dominate the lysosomal membrane.

The decisive experiment came when the researchers exposed both normal and Pla2g15-deficient kidney cells to doxorubicin, a chemotherapy drug that is widely used in the laboratory to inflict DNA damage and trigger senescence. In ordinary cells, doxorubicin raised levels of the senescence-associated protein P21 and forced cells into a pronounced arrest at the G2/M checkpoint of the cell cycle. Cells lacking Pla2g15 responded very differently: P21 expression was significantly lower and G2/M arrest was reduced, indicating that the senescence response had been substantially attenuated. The knockout cells also showed improved mitochondrial and lysosomal health compared with their normal counterparts under the same stress.

Follow-up lipidomics sharpened the picture. Doxorubicin-treated normal cells accumulated several long-chain polyunsaturated BMP species, including BMP42:6, BMP42:8 and BMP44:8, while Pla2g15-deficient cells shifted toward shorter BMP species and away from the long-chain unsaturated forms. This species-specific pattern suggests that the buildup of particular long-chain BMP lipids is not merely a byproduct of senescence but may be mechanistically tied to its development. As the authors state in the paper, “Here, we identify a critical role for lysosomal phospholipid metabolism in senescent TECs,” framing the lipid remodeling as an active participant in the senescent state rather than passive chemistry.

To understand how a lysosomal enzyme could reach into other cellular compartments, the researchers performed proteomic analysis, quantifying more than 3,400 proteins. The knockout cells showed increased abundance of proteins tied to mitochondrial metabolic pathways, including components of NAD+ metabolism and fatty acid oxidation. Among the upregulated proteins were NAMPT and NMNAT3, both involved in generating and recycling NAD+, a molecule central to cellular energy metabolism, and CPT2, an enzyme that shuttles fatty acids into mitochondrial oxidation. The proteomic data also revealed reduced levels of proteins driving cell-cycle progression and ribosomal processes, along with increased expression of LAMP1, a lysosomal membrane protein. “Our findings point to PLA2G15 as a critical regulator of senescence through its role in lysosomal lipid remodelling and mitochondrial metabolism,” the authors conclude. The team is careful to note, however, that direct measurements of mitochondrial metabolic function and lysosomal activity were not performed, so the proposed functional benefits still require confirmation.

The implications for chronic kidney disease are potentially significant, because impaired lipid metabolism, mitochondrial dysfunction and persistent senescence all converge in the damaged aging kidney. By naming PLA2G15 as a regulator of BMP composition and senescence-related changes, the study offers a concrete molecular handle for future interventions aimed at preserving kidney-cell health during aging. Yet the work remains firmly preclinical. The observations in aged mouse kidneys were associative, and the protective effects of Pla2g15 disruption were demonstrated only in cultured mouse cells exposed to doxorubicin, a model that does not fully reproduce natural kidney aging or chronic kidney disease in a living organism. The researchers also emphasize that pharmacological inhibition of PLA2G15 has not been tested, and it is unknown whether a drug-based approach would reproduce the effects seen with genetic deletion.

Several questions will shape the next phase of research. Genetically modified animals, alternative senescence models and direct functional measurements of mitochondria and lysosomes will be needed to establish the biological mechanisms and therapeutic relevance of targeting PLA2G15. Because the mouse experiments involved only males, future studies must also determine whether the same lipid-senescence relationship holds in females. Even with those caveats, the study adds an intriguing new dimension to the biology of aging: the idea that the molecular species of lipids lining the lysosome, not just their total amount, help determine whether a stressed kidney cell quietly exits the cell cycle or locks itself into a damaging senescent state. If that relationship holds up in living animals, selectively modifying BMP metabolism could open a new route to slowing the cellular decline that underlies age-related kidney disease.

Subject of Research: The role of the lysosomal enzyme PLA2G15 and BMP phospholipid metabolism in cellular senescence of kidney tubular cells

Article Title: Targeting PLA2G15 reduces senescence and alters lipid metabolism in kidney cells

Article References: Targeting PLA2G15 reduces senescence and alters lipid metabolism in kidney cells. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: PLA2G15, cellular senescence, kidney aging, lysosomes, BMP phospholipids, chronic kidney disease, mitochondria, lipid metabolism, tubular epithelial cells, CRISPR, NAD+ metabolism, doxorubicin

The genes in question belong to the WRKY family, one of the largest families of transcription factors in plants. Transcription factors are proteins that bind to specific DNA sequences and switch other genes on or off, acting like the conductors of a genetic orchestra. WRKY factors are named for a highly conserved stretch of amino acids, the WRKY motif, and they are known to orchestrate a plant’s reactions to drought, cold, disease, and salinity. Until now, however, no systematic catalogue of WRKY genes existed for Codonopsis pilosula, leaving a gap in understanding how this economically significant edible and medicinal plant mounts its defense against soil stress.

To fill that gap, the researchers scanned the entire genome of the species and identified 47 WRKY genes, which they named CpWRKYs. The genes were not spread evenly across the plant’s genetic blueprint; instead, they were distributed unevenly across eight chromosomes, a pattern that often reflects the uneven pressures of evolution. Using phylogenetic analysis, which compares gene sequences to reconstruct family trees, together with examinations of conserved protein domains and motifs, the team sorted the 47 genes into seven subfamilies. Members of each subfamily shared similar conserved motifs but differed in their gene structures, the arrangement of coding regions and intervening sequences that shapes how each gene is read and regulated.

A second layer of analysis focused on how the family grew over evolutionary time. Collinearity analysis, which looks for stretches of DNA that appear in duplicated blocks across the genome, revealed 13 duplicated gene pairs among the CpWRKYs. This pointed to segmental duplication, the replication of large chromosomal segments, as the main engine driving the expansion of the WRKY family in this species. Such duplication events give evolution raw material to work with: one copy can keep performing the ancestral job while the other is free to mutate and take on new roles, including the fine-tuning of stress responses.

Identifying the genes was only the first step. The real question was which of them actually respond when the plant’s roots hit salty, alkaline soil. To answer it, the researchers turned to transcriptome analysis, a technique that measures which genes are actively being transcribed into RNA under given conditions. When they compared plants exposed to saline-alkali stress with unstressed controls, they found that the differentially expressed WRKY genes, the ones whose activity changed markedly, mostly belonged to three groups: I, IIc, and III. These groups are known in other species to be involved in stress signaling, suggesting that Codonopsis pilosula recruits a familiar cast of molecular players to deal with an unfamiliar challenge.

But gene expression alone does not tell the whole story. Plants respond to stress not only by changing which genes are active but also by altering their metabolism, the chemical reactions that keep cells alive. The team therefore performed metabolic profiling to see which small molecules accumulated or declined under saline-alkali conditions. The results were striking: lipid metabolites, the fat-derived molecules that make up cell membranes and serve as signaling compounds, were the main differentially accumulated metabolites under stress. This makes biological sense, because saline-alkali stress damages membranes and triggers a cascade of lipid-based signaling that helps the plant reorganize its cellular defenses.

The most intriguing finding came when the researchers connected the two data streams. Using gene co-expression network analysis, a computational approach that identifies groups of genes whose activity rises and falls in tandem, they discovered that the genes involved in lipid metabolism were linked to specific WRKY transcription factors. One gene in particular, Cpi05G005333-I, emerged as a hub in this network, suggesting that it may act as a master switch coordinating the lipid-based response to saline-alkali stress. In other words, the WRKY factors appear to sit upstream of the metabolic changes, turning on the machinery that reshapes the plant’s lipid profile when the soil turns hostile.

By combining phylogenetic classification, duplication analysis, transcriptomics, metabolomics, and network modeling, the study offers the first comprehensive portrait of the WRKY family in Codonopsis pilosula and identifies candidate genes that likely participate in the transcriptional response to saline-alkali stress. The work was carried out by researchers at Changzhi Medical College in China, with additional contributions from the Inner Mongolia Key Laboratory of Plants Adversity Adaptation and Genetic Improvement in Cold and Arid Regions at Inner Mongolia Agricultural University, and was supported by funding from Changzhi Medical College and the Fundamental Research Program of Shanxi Province.

The practical implications could be significant. Codonopsis pilosula is not only a staple of traditional herbal medicine but also a crop whose cultivation is expanding into marginal, salt-affected soils. Understanding which WRKY genes drive salt tolerance opens the door to breeding or engineering varieties that can withstand saline-alkali conditions more effectively, whether through conventional selection informed by genetic markers or through targeted genome editing. The lipid connection is particularly interesting because membrane remodeling is a shared feature of stress responses across many plant species, meaning the findings could inform broader efforts to develop stress-resilient crops.

There is still much to confirm. The study identifies candidate genes and networks, but functional validation, the laboratory work of silencing or overexpressing individual genes to see how the plant responds, will be needed to prove which CpWRKYs are truly indispensable for salt tolerance. Nevertheless, the research lays a solid foundation. It demonstrates how a genome-wide, multi-omics approach can turn a medicinal herb into a model for understanding stress adaptation, and it brings scientists one step closer to the goal of growing valuable crops on land that would otherwise remain barren.

Subject of Research: Genome-wide identification of WRKY transcription factors and their role in saline-alkali stress response in Codonopsis pilosula roots

Article Title: Genome-wide identification of CpWRKYs and elucidation of the saline-alkali response mechanism in Codonopsis pilosula roots

Article References: Liu, J., Zhang, X., Jing, X., Zhao, L., Yan, Y., Song, X., Li, Y., Su, W., & Wan, Y. (2026). Genome-wide identification of CpWRKYs and elucidation of the saline-alkali response mechanism in Codonopsis pilosula roots. BMC Plant Biology. https://doi.org/10.1186/s12870-026-09770-6

Image Credits: AI Generated

DOI: 10.1186/s12870-026-09770-6

Keywords: Codonopsis pilosula, WRKY transcription factors, saline-alkali stress, genome-wide analysis, transcriptomics, lipid metabolism, gene co-expression network, segmental duplication, plant stress response, medicinal plants, BMC Plant Biology, transcriptional regulation